Treatment with PSMA radioligand therapy (RLT), with, e.g., 177Lu-PSMA-617 or 177Lu-PSMA-I&T, is not curative but has been effective in reducing tumor burden and increasing life expectancy in patients with mCRPC [6,7,8]. Here, FOLH1 is linked to neoplasm.